𝔖 Bobbio Scriptorium
✦   LIBER   ✦

A multicenter Phase II study of bortezomib in recurrent or metastatic sarcomas

✍ Scribed by Robert G. Maki; Andrew S. Kraft; Kelly Scheu; Jennifer Yamada; Scott Wadler; Cristina R. Antonescu; John J. Wright; Gary K. Schwartz

Publisher
John Wiley and Sons
Year
2005
Tongue
English
Weight
91 KB
Volume
103
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Phase II study of a protracted irinoteca
Phase II study of a protracted irinotecan schedule in children with refractory or recurrent soft tissue sarcoma
✍ Gianni Bisogno; Riccardo Riccardi; Antonio Ruggiero; Giampaolo Arcamone; Arcange πŸ“‚ Article πŸ“… 2006 πŸ› John Wiley and Sons 🌐 English βš– 85 KB πŸ‘ 1 views

## Abstract ## BACKGROUND Irinotecan (CPT‐11) is a novel antineoplastic agent that takes effect by inhibiting topoisomerase I. The Italian Soft Tissue Sarcoma (STS) Committee performed a multiinstitutional Phase II study to evaluate its effect on STS. ## METHODS Over a 2‐year period between 2002

A phase II trial of temozolomide in pati
A phase II trial of temozolomide in patients with unresectable or metastatic soft tissue sarcoma
✍ Susan M. Talbot; Mary Louise Keohan; Mary Hesdorffer; Russell Orrico; Emilia Bag πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons 🌐 English βš– 69 KB πŸ‘ 1 views

## Abstract ## BACKGROUND The objective of this study was to assess the efficacy and toxicity of the imidazotetrazine derivative temozolomide for patients with unresectable or metastatic soft tissue sarcoma. ## METHODS Twenty‐five of 26 patients were eligible and assessable for toxicity and resp